Atlas Trials

Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer

Clinical trial NCT07112209 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT07112209
Sponsor
Zhujiang Hospital
Status
ENROLLING_BY_INVITATION
Phase
Not Applicable
Study type
INTERVENTIONAL
Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer
Start date
2023-11-06
Primary completion
2027-06-10
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.